openPR Logo
Press release

Artificial Pancreas Device System (APDS) Market Is Growing Exponentially In Order To Gain More Demand By 2026 And The Top Manufacturers Are Medtronic, Medtrum, Tandem Diabetes Care, Johnson & Johnson, Beta Bionics, Bigfoot Biomedical

07-01-2019 04:03 PM CET | Health & Medicine

Press release from: Coherent Market Insights - Biotechnology

Artificial Pancreas Device System (APDS)

Artificial Pancreas Device System (APDS)

The global artificial pancreas device system (APDS) market was valued at US$ 64.0 million in 2015 and is expected to witness a moderate CAGR of 18.6% during the forecast period (2016 – 2024). Eating habits of type 1 diabetes patients is highly curtailed, complemented by regular administration of insulin. Type 1 diabetes patients require multiple doses of insulin in a day and all-round the year. Advancements in research and technology has led to commercialization of easy-to-us insulin delivery systems such as insulin pens, pumps, inhaled insulin, and injectors.

Ask For The Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/79

Use of syringes to deliver insulin has become obsolete with the introduction of advanced and easy-to-use insulin delivery systems mentioned above. Moreover, these systems offer the convenience to self-administer insulin at home. An artificial pancreas is a novel concept that promises to revolutionize the entire diabetes market. The system automatically detects glucose level in patient’s blood or plasma and accordingly administers the necessary dosage of insulin. Medtronic’s MiniMed 670G is one such wearable artificial pancreas. The system is automated to monitor glucose levels and deliver insulin through an insulin pump attached to the system. The artificial pancreas system comprises a transmitter, sensor, and insulin pump. This helps in continuous monitoring and diabetes management at ease.

Market Dynamics

The artificial pancreas device system (APDS) market growth would be mainly driven by increasing adoption of the highly useful systems the large base of diabetes type 1 patients, further supplemented by ever increasing incidence of type 1 diabetes. According to the World Health Organization (WHO), number of diabetes patients worldwide increased from 108 million in 1980 to 422 million in 2014. According to Juvenile Diabetes Research Foundation (JDRF), there were around 1.5 million type 1 diabetics worldwide in 2015. JDRF funds research in diabetes 1 and the non-profit organization expected the first artificial pancreas to be commercialized in 2017. According to the Center for Disease Control and Prevention (CDC), type 1 diabetes accounts for around 5% of the total diagnosed diabetes cases in adults in the U.S. Developed regions are expected to dominate the artificial pancreas device system (APDS) market size, as these regions are early adopters of disruptive technologies.

Strategic collaborations fostering artificial pancreas device system (APDS) market growth

There were over 20 projects undertaken by the industry payers in 2015 with respect to development of artificial pancreas device system (APDS). Bigfoot Biomedical acquired Asante’s FDA approved Snap insulin pump technology in 2015 and at the same time signed a development agreement with Dexcom to integrate Dexcom’s CGM in its under development artificial pancreas device system (APDS). Dexcom is in collaboration with many other market players such as Insulet Corporation, Animas Corporation, and International Diabetes Closed Loop wherein, these companies would be incorporating Dexcom’s CGM in their artificial pancreas device system (APDS). Such collaborations are expected to expedite market entry for new artificial pancreas device system (APDS)s and thus drive the growth of artificial pancreas device system (APDS) market.

Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/79

Key companies covered as a part of this study include Medtronic, Medtrum, Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Bigfoot Biomedical, and Insulet Corporation

Technological advancements to drive growth of the global artificial pancreas device system (APDS) market

In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS) MiniMed 670G which is an automated system. The continuous glucose monitor in the system automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes beyond the acceptable limit. Thus, there is no need for the user to stimulate the release of insulin every time the glucose level is abnormal. This provide the user freedom to perform his/her daily activities. Such advancement in T1D management is expected to be highly preferred by the users and medical community, leading to higher advocacy to use this device especially among the patient group using insulin pumps. Moreover, in mid-2018, a study will test a bihormonal “bionic pancreas” system at the Massachusetts General Hospital (Boston) and Boston University. This would further fuel the artificial pancreas device system (APDS) market growth and attract more investments.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Artificial Pancreas Device System (APDS) Market Is Growing Exponentially In Order To Gain More Demand By 2026 And The Top Manufacturers Are Medtronic, Medtrum, Tandem Diabetes Care, Johnson & Johnson, Beta Bionics, Bigfoot Biomedical here

News-ID: 1792933 • Views: 1300

More Releases from Coherent Market Insights - Biotechnology

Recombinant Protein Market To Witness Robust Expansion Throughout The Forecast P …
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Biosimilar Pipeline Analysis Market Outlook 2019: Rapidly Develop by key Players …
Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness
Cancer Biomarkers Market Rapid Growth 2019 by leading players BioMerieux S.A., B …
The global cancer biomarkers market is projected to witness significant growth over the forecast period, owing to rising incidence and prevalence of various cancer types, including breast cancer, lung cancer, kidney cancer, liver cancer, prostate cancer, and among others. Moreover, other factors impacting growth of cancer biomarkers market includes rising research and development activities in developing cancer biomarker and rising demand for personalized medicine in cancer therapies. Free Request Sample Copy
Diabetes Vaccine Market Scrutinized in New Research 2018-2026
Diabetes is one of most prevalent chronic diseases worldwide. According to WHO (World Health Organization), diabetes was one of top three leading causes of mortality in 2012. The diabetes vaccine currently under development has significant potential in younger age group (Below 20 years age), who are characterized by a stronger autoimmune response to combat infection from specific viruses. Diabetes vaccine is being developed to strengthen the body’s response against enterovirus

All 5 Releases


More Releases for APDS

Global Artificial Pancreas Device System Market | APDS Industry Report Forecasts …
Global Artificial Pancreas Market Analysis By Type CTR (control to range) and CTT (control to target); By End User (hospitals, medical centers, and others); by Geography (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) to 2025. The report provides forecast and analysis of the global artificial pancreas market. It provides market overview of global artificial pancreas Market of in terms of revenue (in US$ Mn). Furthermore, the
Artificial Pancreas Device System (APDS) Market - Global Industry Insights, Tren …
Administering insulin on daily basis is cumbersome for type 1 diabetes (T1D) patients in a busy lifestyle. While devices such as insulin pumps, pens, and jet injectors have made living with diabetes less stressful by ridding users of relatively painful insulin delivering devices such as needles and syringes. Juvenile Diabetes Research Foundation (JDRF) is working in collaboration with many industry players such as Medtronic, Inc., Johnson & Johnson, and Tandem
Global Artificial Pancreas Device System (APDS) Market Forecast till 2024
Artificial Pancreas Device System (APDS) – Putting the Ease in Diabetes Management Administering insulin on daily basis is cumbersome for type 1 diabetes (T1D) patients in a busy lifestyle. While devices such as insulin pumps, pens, and jet injectors have made living with diabetes less stressful by ridding users of relatively painful insulin delivering devices such as needles and syringes. Juvenile Diabetes Research Foundation (JDRF) is working in collaboration with many
Artificial Pancreas Device System (APDS) Market , Growth and Forecast up, 2018-2 …
Qyresearchreports include new market research report “Global Artificial Pancreas Device System (APDS) Market Research Report 2018” to its huge collection of research reports. Global Artificial Pancreas Device System (APDS) market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including Medtronic Bigfoot Biomedical Johnson & Johnson Tandem Diabetes Care Inc Pancreum Inc TypeZero Technologies, LLC Beta Bionics Download Free exclusive Sample of this report: https://www.qyresearchreports.com/sample/sample.php?rep_id=1677196&type=S From the regional segmentation point of
Global Artificial Pancreas Device System (APDS) Market Sales, Demand, Status & F …
An up-to-date medical industry research report 2018 has been disclosed by Market Research Hub highlighting the title “Global Artificial Pancreas Device System (APDS) Market Report 2018” which provides an outlook for current market value as well as the expected forecast including Rate on Investment (ROI) together with the growing CAGR near XX% during 2018-2025. The report Global Artificial Pancreas Device System (APDS) Market studies the casing heads market worldwide, especially
Global Artificial Pancreas Device System (APDS) Market Size will Reach US$ 0.25 …
Technological advancements to drive growth of the global artificial pancreas device system (APDS) market In 2016, the U.S. FDA approved a hybrid closed-loop artificial pancreas device system (APDS) MiniMed 670G which is an automated system. The continuous glucose monitor in the system automatically sends signals to the insulin pump to deliver insulin when the glucose level in body goes beyond the acceptable limit. Thus, there is no need for the user